STAAR Surgical (NASDAQ:STAA) Given Average Rating of "Hold" by Analysts

Shares of STAAR Surgical (NASDAQ:STAA - Get Free Report) have received an average rating of "Hold" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $25.29.

Several brokerages have commented on STAA. Stifel Nicolaus cut their target price on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Mizuho downgraded shares of STAAR Surgical from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. StockNews.com downgraded shares of STAAR Surgical from a "hold" rating to a "sell" rating in a research report on Thursday, February 13th. Canaccord Genuity Group decreased their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. Finally, BTIG Research downgraded STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th.

STAAR Surgical Stock Up 4.6 %

NASDAQ STAA traded up $0.75 on Wednesday, hitting $16.89. The company's stock had a trading volume of 485,153 shares, compared to its average volume of 794,355. The firm has a market cap of $833.10 million, a PE ratio of -41.20 and a beta of 0.75. The company's 50-day moving average is $17.07 and its 200 day moving average is $23.26. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $49.86.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 3,620 shares of the stock in a transaction on Thursday, March 27th. The shares were purchased at an average price of $17.48 per share, for a total transaction of $63,277.60. Following the completion of the acquisition, the insider now owns 12,424,944 shares in the company, valued at approximately $217,188,021.12. This represents a 0.03 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders bought 1,742,581 shares of company stock valued at $28,407,543. Company insiders own 1.00% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Exchange Traded Concepts LLC lifted its position in STAAR Surgical by 25.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 45,568 shares of the medical instruments supplier's stock valued at $803,000 after acquiring an additional 9,194 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of STAAR Surgical by 75.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 21,234 shares of the medical instruments supplier's stock valued at $374,000 after buying an additional 9,125 shares during the last quarter. SG Americas Securities LLC grew its holdings in STAAR Surgical by 123.1% during the first quarter. SG Americas Securities LLC now owns 49,072 shares of the medical instruments supplier's stock worth $865,000 after buying an additional 27,075 shares in the last quarter. GAMMA Investing LLC raised its position in STAAR Surgical by 4,086.0% in the 1st quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier's stock valued at $258,000 after buying an additional 14,301 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in STAAR Surgical by 13.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier's stock valued at $2,684,000 after acquiring an additional 13,075 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.